tailieunhanh - Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: A pilot study

Recent vasodilating drugs have improved prognosis of Pulmonary arterial hypertension (PAH). Some reports describe the merits of combination therapies for PAH, and this study evaluated the efficacy and safety of phosphodiesterase type 5 inhibitors (PDE5i) combination therapy, using sildenafil and tadalafil, for multi-drug-resistant PAH. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN